Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Multiple myeloma (MM), a plasma cell disorder, is the second most common hematologic
malignancy in the U.S. No standard curative therapy has yet been found. A variety of
therapeutic measures including high dose melphalan, induction therapy, and continuous therapy
have been used but the goal of complete response without relapse has not been achieved. More
active treatment regimens and better tools for response assessment are needed.